Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.

Hepato-gastroenterology - 1 May 2015

Kawahara Daisuke, Fujita Fumihiko, Hayashi Hideki, Matsuyama Toshifumi, Eguchi Susumu

Abstract excerpt

BACKGROUND/AIMS: Though serum p53 antibody has been widely used, it is mentioned that it is not related to clinical parameters of colorectal cancer (CRC) and has no prognostic significance in long-term follow-up. The aim of this study was to explore the possibility to increase the value of p53 antibody in combination with carcinoembryonic antigen (CEA) and CA19-9 for post operation follow up. METHODOLOGY: One...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantibodies
Share to CA-19-9 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoembryonic Antigen

Share to Colectomy

Share to Early Detection of Cancer

Share to Kaplan-Meier Estimate

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 26897942

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.PMID 26897942Read ↗

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?Semantic proximity Read ↗

Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients.Semantic proximity Read ↗

Clinical Diagnostic Value for Colorectal Cancer Based on Serum CEA, CA24-2 and CA19-9Semantic proximity Read ↗

Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.Semantic proximity Read ↗

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.Semantic proximity Read ↗

The role of tumor markers and biomarkers in colorectal cancer.Semantic proximity Read ↗

Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.Semantic proximity Read ↗

p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.Semantic proximity Read ↗

Effect of KRAS mutations and p53 expression on the postoperative prognosis of patients with colorectal cancer.Semantic proximity Read ↗

Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.Semantic proximity Read ↗

Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.Semantic proximity Read ↗

Clinical significance of p53 protein expression and TP53 mutation status in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.